22:12 , Jul 17, 2019 |  BC Extra  |  Preclinical News

July 17 Preclinical Quick Takes: Using CRISPR to edit TCRs, plus AAVs with synthetic promoters and AI for cancer diagnosis

CRISPR can modify TCRs to reprogram T cells  A Technical University Munich and Juno Therapeutics Inc. team led by TUM professor Dirk Busch used CRISPR to modify T cell receptors and create engineered T cells....
13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
21:28 , Jun 25, 2019 |  BC Extra  |  Company News

WuXi AppTec raising U.S. profile to counter political attacks

WuXi AppTec plans to raise its profile in the U.S. in the hope that a better understanding of its activities will de-escalate political attacks on the company, co-CEO Edward Hu told BioCentury. While restrictions on...
00:43 , Jun 14, 2019 |  BC Extra  |  Company News

Tessa forms JV with biohub to bring its cell therapies to China

Tessa is hoping a JV with a Guangzhou biohub will speed access to the company’s virus-specific T cell therapies for cancers prevalent in China. The Singapore-based company, which partnered Thursday with GSGKC to develop and...
23:49 , Jun 6, 2019 |  BC Extra  |  Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
00:01 , May 23, 2019 |  BioCentury  |  Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
23:13 , Mar 26, 2019 |  BC Extra  |  Company News

Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted. The hypoimmunogenic stem cells are derived...